Athersys stem cell treatment for stroke fails trial, but still hope for patients – cleveland.com
cleveland.com |
Athersys stem cell treatment for stroke fails trial, but still hope for patients
cleveland.com Cleveland-based biotech Athersys believes its MultiStem stem cell treatment for stroke, which failed to best a placebo in a Phase 2 trial, may still be helpful for a subset of patients who showed marked improvement in the trial. The company plans to … |
